91 related articles for article (PubMed ID: 7796410)
41. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y
Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recombinant endostatin protein.
Liang ZH; Wu PH; Li L; Xue G; Zeng YX; Huang WL
Chin Med J (Engl); 2004 Dec; 117(12):1809-14. PubMed ID: 15603709
[TBL] [Abstract][Full Text] [Related]
43. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
Shariat SF; Desai S; Song W; Khan T; Zhao J; Nguyen C; Foster BA; Greenberg N; Spencer DM; Slawin KM
Cancer Res; 2001 Mar; 61(6):2562-71. PubMed ID: 11289132
[TBL] [Abstract][Full Text] [Related]
44. [Clinical application for gene therapy in prostate cancer].
Gotoh A; Kamidono S; Chung LW
Hinyokika Kiyo; 1997 Nov; 43(11):829-33. PubMed ID: 9436031
[TBL] [Abstract][Full Text] [Related]
45. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.
Hull GW; Mccurdy MA; Nasu Y; Bangma CH; Yang G; Shimura S; Lee HM; Wang J; Albani J; Ebara S; Sato T; Timme TL; Thompson TC
Clin Cancer Res; 2000 Oct; 6(10):4101-9. PubMed ID: 11051263
[TBL] [Abstract][Full Text] [Related]
46. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
[TBL] [Abstract][Full Text] [Related]
47. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.
Ji L; Fang B; Yen N; Fong K; Minna JD; Roth JA
Cancer Res; 1999 Jul; 59(14):3333-9. PubMed ID: 10416589
[TBL] [Abstract][Full Text] [Related]
48. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
49. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
50. Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy.
Takahashi S; Kato K; Nakamura K; Nakano R; Kubota K; Hamada H
Cancer Sci; 2011 Apr; 102(4):808-14. PubMed ID: 21214674
[TBL] [Abstract][Full Text] [Related]
51. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells.
He D; Mu ZM; Le X; Hsieh JT; Pong RC; Chung LW; Chang KS
Cancer Res; 1997 May; 57(10):1868-72. PubMed ID: 9157977
[TBL] [Abstract][Full Text] [Related]
52. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470.
Pu YS; Do KA; Luo W; Logothetis CJ; Lin SH
Anticancer Drugs; 2002 Aug; 13(7):743-9. PubMed ID: 12187331
[TBL] [Abstract][Full Text] [Related]
53. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.
Ko SC; Gotoh A; Thalmann GN; Zhau HE; Johnston DA; Zhang WW; Kao C; Chung LW
Hum Gene Ther; 1996 Sep; 7(14):1683-91. PubMed ID: 8886839
[TBL] [Abstract][Full Text] [Related]
54. Structure and function of C-CAM1: effects of the cytoplasmic domain on cell aggregation.
Lin SH; Luo W; Earley K; Cheung P; Hixson DC
Biochem J; 1995 Oct; 311 ( Pt 1)(Pt 1):239-45. PubMed ID: 7575460
[TBL] [Abstract][Full Text] [Related]
55. Purification and characterization of human cell--cell adhesion molecule 1 (C-CAM1) expressed in insect cells.
Phan D; Han E; Birrell G; Bonnal S; Duggan L; Esumi N; Gutstein H; Li R; Lopato S; Manogaran A; Pollak ES; Ray A; Reddi PP; Reichert AS; Struffi P; Tiscornia G; Ximenez-Fyvie LA; Zhang H; Lin SH
Protein Expr Purif; 2001 Mar; 21(2):343-51. PubMed ID: 11237697
[TBL] [Abstract][Full Text] [Related]
56. A short isoform of carcinoembryonic-antigen-related rat liver cell-cell adhesion molecule (C-CAM/gp110) mediates intercellular adhesion. Sequencing and recombinant functional analysis.
Lucka L; Cichocka I; Bäumler K; Bechler K; Reutter W
Eur J Biochem; 1995 Dec; 234(2):527-35. PubMed ID: 8536699
[TBL] [Abstract][Full Text] [Related]
57. Exploration of target molecules for prostate cancer gene therapy.
Suzuki K; Nakamura K; Kato K; Hamada H; Tsukamoto T
Prostate; 2007 Aug; 67(11):1163-73. PubMed ID: 17516570
[TBL] [Abstract][Full Text] [Related]
58. Cell adhesion activity of the short cytoplasmic domain isoform of C-CAM (C-CAM2) in CHO cells.
Olsson H; Wikström K; Kjellström G; Obrink B
FEBS Lett; 1995 May; 365(1):51-6. PubMed ID: 7774714
[TBL] [Abstract][Full Text] [Related]
59. Design of solid lipid nanoparticles for gene delivery into prostate cancer.
de Jesus MB; Ferreira CV; de Paula E; Hoekstra D; Zuhorn IS
J Control Release; 2010 Nov; 148(1):e89-90. PubMed ID: 21529650
[No Abstract] [Full Text] [Related]
60. Structure and function of C-CAM1. The first immunoglobulin domain is required for intercellular adhesion.
Cheung PH; Luo W; Qiu Y; Zhang X; Earley K; Millirons P; Lin SH
J Biol Chem; 1993 Nov; 268(32):24303-10. PubMed ID: 8226979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
